RESUMEN
The classical phosphodiesterase 3A (PDE3A) inhibitors provide relaxation of the vasculature system via increasing the cellular level of cyclic adenosine monophosphate (cAMP) and proved to be useful in the management of congestive heart failure. Consequently, the present paper deals with the development of novel pyrazole derivatives tethered with substituted 1,3,5-triazine derivatives in search for novel PDE3 inhibitors. The synthesis of designed inhibitors was realized in a multi-step reaction and the structures were ascertained with the help of various spectroscopic techniques. Subsequently, these analogs were tested for their inhibitory activities against PDE3 enzymes, where they exhibited considerable inhibition, revealing 9g as the most promising inhibitor of the class. In a docking study, the morpholine fragment of compound 9g was efficiently engulfed in the small pocket of the active site lined by Gly940 and Pro941. The substituted aromatic ring of the core scaffold was found to be positioned deep in the cavity bordered by Tyr829, Asn830, Leu850, Glu851, and Thr893. Moreover, it considerably improved the contractility of cardiac muscles without altering the heart beat frequency in experimental subjects.
Asunto(s)
Cardiotónicos/química , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 3/metabolismo , Inhibidores de Fosfodiesterasa 3/química , Triazinas/química , Animales , Cardiotónicos/síntesis química , Cardiotónicos/farmacología , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 3/química , Frecuencia Cardíaca/efectos de los fármacos , Masculino , Simulación del Acoplamiento Molecular , Contracción Miocárdica/efectos de los fármacos , Inhibidores de Fosfodiesterasa 3/síntesis química , Inhibidores de Fosfodiesterasa 3/farmacología , Ratas Wistar , Triazinas/síntesis química , Triazinas/farmacologíaRESUMEN
A series of novel 2-(4-(1H-tetrazol-5-yl)-1H-pyrazol-1-yl)-4-(4-phenyl)thiazole derivatives, 6(a-o) were designed, synthesized and evaluated for inhibitory activity against human PDE3A and PDE3B. In PDE3 assay, entire set of targeted analogs showed considerable inhibition of PDE3A (IC50=0.24 ± 0.06-16.42 ± 0.14 µM) over PDE3B (IC50=2.34 ± 0.13-28.02 ± 0.03 µM). Among the synthesized derivatives, compound 6d exhibited most potent inhibition of PDE3A with IC50=0.24 ± 0.06 µM than PDE3B (IC50=2.34 ± 0.13 µM). This compound was further subjected for evaluation of cardiotonic activity (contractile and chronotropic effects) in comparison with Vesnarinone. Results showed that, it selectively modulates the force of contraction (63%± 5) rather than frequency rate (23% ± 2) at 100 µM. Docking study of above compound was also carried out in the active site of PDE3 protein model to give proof to the mechanism of action of designed inhibitor. Further, in sub-acute toxicity experiment in Swiss-albino mice, it was found to be non-toxic up to 100mg/kg dose for 28days.
Asunto(s)
Cardiotónicos/química , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 3/química , Diseño de Fármacos , Inhibidores de Fosfodiesterasa 3/química , Pirazoles/química , Tiazoles/química , Animales , Sitios de Unión , Cardiotónicos/síntesis química , Cardiotónicos/metabolismo , Dominio Catalítico , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 3/metabolismo , Evaluación Preclínica de Medicamentos , Humanos , Masculino , Simulación del Acoplamiento Molecular , Inhibidores de Fosfodiesterasa 3/síntesis química , Inhibidores de Fosfodiesterasa 3/metabolismo , Unión Proteica , Pirazoles/metabolismo , Ratas , Ratas Wistar , Tiazoles/síntesis química , Tiazoles/metabolismo , Pruebas de ToxicidadRESUMEN
Phosphodiesterases (PDEs) have been studied in a variety of tumours; data have suggested that the levels of PDE activities are elevated and, therefore, the ratios of cGMP to cAMP are affected. In addition, PDE inhibitors are potential targets for tumour cell growth inhibition and induction of apoptosis. Nonselective PDE inhibitors, such as theophylline or aminophylline, are known regulators of growth in a variety of carcinoma cell lines, suggesting a potential role for PDE inhibitors as anticancer drugs. In the current study, we reported the synthesis of novel derivatives of 6-aryl-4-imidazolyl-2-imino-1,2-dihydropyridine-3-carbonitriles (Ia,b,c) and their 2-oxo isosteres (IIa,b,c,d). All the compounds were evaluated for their PDE3A inhibitory effects, as well as their cytotoxic effects on MCF-7 and HeLa cell lines. Moreover, structure-activity relationships were studied. 4-(1-benzyl-2-ethylthio-5-imidazolyl)-6-(4-bromophenyl)-2-imino-1,2-dihydropyridine-3-carbonitrile (Ib) exhibited the strongest PDE3A inhibitory effects with an IC50 of 3.76±1.03nM. Compound Ib also showed the strongest cytotoxic effects on both the HeLa and MCF-7 cells with an IC50 of 34.3±2.6µM and 50.18±1.11µM, respectively. There was a direct correlation between PDE3 inhibition and anticancer activity for the synthesised compounds. The data reported here support our view that PDEs represent promising cellular targets for antitumor treatment.
Asunto(s)
Antineoplásicos/química , Antineoplásicos/farmacología , Neoplasias/enzimología , Inhibidores de Fosfodiesterasa 3/química , Inhibidores de Fosfodiesterasa 3/farmacología , Piridinas/química , Piridinas/farmacología , Antineoplásicos/síntesis química , Células HeLa , Humanos , Células MCF-7 , Neoplasias/tratamiento farmacológico , Inhibidores de Fosfodiesterasa 3/síntesis química , Hidrolasas Diéster Fosfóricas/metabolismo , Piridinas/síntesis químicaRESUMEN
(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one (KCA-1490) exhibits moderate dual PDE3/4-inhibitory activity and promises as a combined bronchodilatory/anti-inflammatory agent. N-alkylation of the pyridazinone ring markedly enhances potency against PDE4 but suppresses PDE3 inhibition. Addition of a 6-aryl-4,5-dihydropyridazin-3(2H)-one extension to the N-alkyl group facilitates both enhancement of PDE4-inhibitory activity and restoration of potent PDE3 inhibition. Both dihydropyridazinone rings, in the core and extension, can be replaced by achiral 4,4-dimethylpyrazolone subunits and the core pyrazolopyridine by isosteric bicyclic heteroaromatics. In combination, these modifications afford potent dual PDE3/4 inhibitors that suppress histamine-induced bronchoconstriction in vivo and exhibit promising anti-inflammatory activity via intratracheal administration.
Asunto(s)
Antiinflamatorios/química , Broncodilatadores/química , Inhibidores de Fosfodiesterasa 3/química , Inhibidores de Fosfodiesterasa 4/química , Administración por Inhalación , Animales , Antiinflamatorios/síntesis química , Antiinflamatorios/farmacología , Líquido del Lavado Bronquioalveolar/citología , Broncodilatadores/síntesis química , Broncodilatadores/farmacología , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 3/química , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 3/metabolismo , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 4/química , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 4/metabolismo , Diseño de Fármacos , Leucocitos/efectos de los fármacos , Inhibidores de Fosfodiesterasa 3/síntesis química , Inhibidores de Fosfodiesterasa 3/farmacología , Inhibidores de Fosfodiesterasa 4/síntesis química , Inhibidores de Fosfodiesterasa 4/farmacología , Unión Proteica , Piridazinas/química , Piridinas/química , Ratas , Relación Estructura-ActividadRESUMEN
Twenty-six 2-pyridone derivatives (8a-8z), which are structurally analogous to amrinone and milrinone two important cardiotonic drugs, are synthesized and characterized. The synthesis of 2-pyridone derivatives involves addition, followed by cyclization between Baylis-Hillman acetates (7a-7k) and enamino esters or nitriles (3a-3e). Thus synthesized pyridones were subjected to PDE3 inhibitory activity, 14 pyridones were found to be hits out of 26 pyridones synthesized and out of 14 hits, there are 5 pyridones found to be lead compounds having excellent PDE3 inhibitory activity. Further we have carried out computational analysis to understand protein/enzyme and 2-pyridone derivative interactions to identify amino acid residues involved in the vicinity of binding and compared with milrinone drug.
Asunto(s)
Cardiotónicos/síntesis química , Cardiotónicos/farmacología , Insuficiencia Cardíaca/tratamiento farmacológico , Inhibidores de Fosfodiesterasa 3/síntesis química , Inhibidores de Fosfodiesterasa 3/farmacología , Agregación Plaquetaria/efectos de los fármacos , Piridonas/farmacología , Cardiotónicos/química , Relación Dosis-Respuesta a Droga , Humanos , Modelos Moleculares , Estructura Molecular , Inhibidores de Fosfodiesterasa 3/química , Piridonas/química , Relación Estructura-ActividadRESUMEN
(-)-6-(7-Methoxy-2-trifluoromethylpyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydro-3-(2H)-pyridazinone (KCA-1490) is a dual PDE3/4 inhibitor that exhibits potent combined bronchodilatory and anti-inflammatory activity. A survey of potential bicyclic heteroaromatic replacement subunits for the pyrazolo[1,5-a]pyridine core of KCA-1490 has identified the 4-methoxy-2-(trifluoromethyl)benzo[d]thiazol-7-yl and 8-methoxy-2-(trifluoromethyl)quinolin-5-yl analogues as dual PDE3/4-inhibitory compounds that potently suppress histamine-induced bronchoconstriction and exhibit anti-inflammatory activity in vivo.
Asunto(s)
Inhibidores de Fosfodiesterasa 3/química , Inhibidores de Fosfodiesterasa 3/farmacología , Inhibidores de Fosfodiesterasa 4/química , Inhibidores de Fosfodiesterasa 4/farmacología , Antiinflamatorios/síntesis química , Antiinflamatorios/química , Antiinflamatorios/farmacología , Compuestos Bicíclicos Heterocíclicos con Puentes/síntesis química , Compuestos Bicíclicos Heterocíclicos con Puentes/química , Compuestos Bicíclicos Heterocíclicos con Puentes/farmacología , Broncoconstricción/efectos de los fármacos , Broncodilatadores/síntesis química , Broncodilatadores/química , Broncodilatadores/farmacología , Diseño de Fármacos , Humanos , Modelos Moleculares , Inhibidores de Fosfodiesterasa 3/síntesis química , Inhibidores de Fosfodiesterasa 4/síntesis química , Piridinas/síntesis química , Piridinas/química , Piridinas/farmacología , Relación Estructura-ActividadRESUMEN
A structural survey of pyrazolopyridine-pyridazinone phosphodiesterase (PDE) inhibitors was made with a view to optimization of their dual PDE3/4-inhibitory activity for respiratory disease applications. These studies identified (-)-6-(7-methoxy-2-trifluoromethylpyrazolo[1,5-a]pyridine-4-yl)-5-methyl-4,5-dihydro-3-(2H)-pyridazinone (KCA-1490, compound 2ac) as a compound with potent combined bronchodilatory and anti-inflammatory activity and an improved therapeutic window over roflumilast.
Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Broncodilatadores/farmacología , Diseño de Fármacos , Inhibidores de Fosfodiesterasa 3/farmacología , Inhibidores de Fosfodiesterasa 4/farmacología , Pirazoles/farmacología , Piridinas/farmacología , Animales , Antiinflamatorios no Esteroideos/síntesis química , Antiinflamatorios no Esteroideos/química , Broncodilatadores/síntesis química , Broncodilatadores/química , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 3/metabolismo , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 4/metabolismo , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Cobayas , Estructura Molecular , Inhibidores de Fosfodiesterasa 3/síntesis química , Inhibidores de Fosfodiesterasa 3/química , Inhibidores de Fosfodiesterasa 4/síntesis química , Inhibidores de Fosfodiesterasa 4/química , Pirazoles/síntesis química , Pirazoles/química , Piridinas/síntesis química , Piridinas/química , Ratas , Estereoisomerismo , Relación Estructura-ActividadRESUMEN
BACKGROUND: Clinical use of selective PDE3 inhibitors as cardiotonic agents is limited because of their chronotropic and lipolytic side effects. In our previous work, we synthesized a new PDE3 inhibitor named MC2 (6-[4-(4-methylpiperidin-1-yl)-4-oxobutoxy]-4-methylquinolin-2(1H)-one) which produced a high positive inotropic action with a negative chronotropic effect. This work was done to evaluate the effects of MC2 on adipocytes and compare its effects with those of amrinone and cilostamide. METHODS: Preadipocytes were isolated from rat adipose tissue and differentiated to adipocyte in the presence of cilostamide, amrinone or MC2. Lipolysis and adipogenesis was evaluated by measuring glycerol level and Oil Red O staining, respectively. Adipocyte proliferation and apoptosis were determined with MTT assay and Annexin V/PI staining, respectively. RESULTS: Differentiation to adipocyte was induced by amrinone but not by cilostamide or MC2. Basal and isoproterenol-stimulated lipolysis significantly increased by cilostamide (p<0.05). Similarly, amrinone enhanced the stimulated lipolysis (p<0.01). On the other hand, MC2 significantly decreased both adipogenesis (p<0.05) and stimulated lipolysis (p<0.001). Also, incubation of differentiated adipocytes with MC2 caused the loss of cell viability, which was associated with the elevation in apoptotic rate (p<0.05). CONCLUSION: Our data indicate that selective PDE3 inhibitors produce differential effects on adipogenesis and lipolysis. MC2 has proapoptotic and antilipolytic effects on adipocytes and does not stimulate adipogenesis. Therefore, in comparison with the clinically available selective PDE3 inhibitors, MC2 has lowest metabolic side effects and might be a good candidate for treatment of congestive heart failure.